us clinical guidance

Venous thromboembolism (DVT and pulmonary embolism)

Current US diagnosis, severity assessment, anticoagulation, disposition and follow-up priorities for DVT and acute pulmonary embolism.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults with suspected or confirmed lower-extremity deep-vein thrombosis or acute pulmonary embolism. The ASH treatment source addresses people without cancer; pregnancy, active cancer, pediatrics, unusual-site thrombosis, heparin-induced thrombocytopenia and severe kidney or liver disease require the matching specialist source.
sources for this section:AHA/ACC PE 2026ASH VTE 2020

The Bottom Line

  • Use validated clinical probability and objective testing to confirm VTE; do not diagnose or exclude DVT or PE from symptoms alone.
  • For acute PE, apply the 2026 AHA/ACC A-to-E clinical categories to combine symptoms, severity scores, biomarkers, right-ventricular findings and cardiopulmonary failure.
  • Asymptomatic category A PE can be discharged from the emergency department, and early discharge is generally recommended for category B when a safe outpatient system is in place; categories C through E should be hospitalized.
  • When oral anticoagulation is suitable, the 2026 PE guideline recommends a direct oral anticoagulant over a vitamin-K antagonist unless contraindicated; ASH similarly favors DOACs for most eligible DVT/PE patients without cancer.
  • After PE, assess symptoms and functional limitation at each visit for at least one year to detect chronic thromboembolic pulmonary disease or another cause of persistent dyspnea.
sources for this section:AHA/ACC PE 2026ASH VTE 2020

Practical clinical workflow

1
Assess stability first, then combine a validated pretest-probability approach with D-dimer or the appropriate compression-ultrasound or pulmonary vascular imaging pathway.
2
For confirmed PE, assign the current AHA/ACC clinical category and document right-ventricular findings, biomarkers, bleeding risk, comorbidity and social suitability for outpatient care.
3
Choose anticoagulant, setting and initial route from diagnosis, clinical category, kidney and liver function, pregnancy, cancer, interactions, adherence and cost.
4
Identify whether a major reversible risk factor, persistent risk factor or no major reversible factor is present and plan the primary and extended treatment phases accordingly.
5
Arrange early safety review, adherence and bleeding assessment, and PE-specific follow-up for recurrence, dyspnea and functional recovery.
sources for this section:AHA/ACC PE 2026ASH VTE 2020

Safety boundaries and escalation

  • Persistent hypotension, incipient cardiopulmonary failure, severe hypoxemia, syncope or rapidly worsening right-heart strain requires hospital escalation and expert PE response; advanced reperfusion therapies are not routine outpatient care.
  • Verify active bleeding, platelet count when relevant, kidney and liver function, pregnancy, interactions, weight and procedural plans before anticoagulation.
  • Do not use a low severity score alone to discharge someone without reliable access to medicine, follow-up, emergency return and social support.
  • New bleeding, recurrent chest pain or dyspnea, unilateral swelling, neurologic symptoms or hemodynamic change during treatment needs urgent reassessment.
sources for this section:AHA/ACC PE 2026ASH VTE 2020

Localization

US disposition uses the 2026 AHA/ACC PE categories and local emergency, PERT and outpatient infrastructure. Apply current FDA labeling and payer coverage, and use separate ASH guidance for cancer, pregnancy and other special populations.
sources for this section:AHA/ACC PE 2026ASH VTE 2020

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American College of Cardiology and American Heart Association Joint Committee on Clinical Practice Guidelines2026 Guideline for the Evaluation and Management of Acute Pulmonary Embolism in AdultsDOI 10.1161/CIR.0000000000001415 路 published 2026-02-19 路 accessed 2026-08-20
    view source
  2. American Society of HematologyAmerican Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolismReviewed by ASH expert work group in 2022 and retained with annual evidence monitoring; page checked 2026-08-20 路 published 2020-10-02 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.